Literature DB >> 7263664

Comparative study of the carbohydrate moieties of rat and human plasma alpha 1-acid glycoproteins.

H Yoshima, A Matsumoto, T Mizuochi, T Kawasaki, A Kobata.   

Abstract

Rat and human alpha 1-acid glycoproteins contain 5 and 6 acidic asparagine-linked sugar chains in 1 molecule, respectively. The structures of these sugar chains were studied by sequential exoglycosidase digestion in combination with methylation analysis after being released from the polypeptide back bone by hydrazinolysis. All oligosaccharides obtained from both glycoproteins contain N-acetylneuraminic acid. Sialidase digestion of the acidic oligosaccharides from rat sample released three biantennary complex type sugar chains and three triantennary complex type sugar chains, the outer chains of which are composed of Gal beta 1 leads to 3GlcNAc and/or Gal beta 1 leads to 4GlcNAc. In the original acidic oligosaccharides, sialic acids occur as three type linkages: NeuAc alpha 2 leads to 3Gal, NeuAc alpha 2 leads to 6Gal, and Gal beta 1 leads to 3(NeuAc alpha 2 leads to 6)GlcNAc. In addition to the five sugar chains reported by Fournet, B., Montreuil, J., Strecker, G., Dorland, L., Haverkamp, J., Vilegenthart, J. F. G., Binette, J. P., and Schmid, K. ((1978) Biochemistry 17, 5206-5214), the structures of three new sugar chains of human alpha 1-acid glycoprotein were elucidated.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7263664

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  27 in total

1.  Analysis of the five glycosylation sites of human alpha 1-acid glycoprotein.

Authors:  M J Treuheit; C E Costello; H B Halsall
Journal:  Biochem J       Date:  1992-04-01       Impact factor: 3.857

2.  The carbohydrate moiety of alpha-galactosidase from Trichoderma reesei.

Authors:  A N Savel'ev; E V Eneyskaya; L S Isaeva-Ivanova; K A Shabalin; A M Golubev; K N Neustroev
Journal:  Glycoconj J       Date:  1997-12       Impact factor: 2.916

3.  Structural insights into differences in drug-binding selectivity between two forms of human alpha1-acid glycoprotein genetic variants, the A and F1*S forms.

Authors:  Koji Nishi; Tomomi Ono; Teruya Nakamura; Naoko Fukunaga; Miyoko Izumi; Hiroshi Watanabe; Ayaka Suenaga; Toru Maruyama; Yuriko Yamagata; Stephen Curry; Masaki Otagiri
Journal:  J Biol Chem       Date:  2011-02-24       Impact factor: 5.157

4.  Unusual ultrastructure of complement-component-C4b-binding protein of human complement by synchrotron X-ray scattering and hydrodynamic analysis.

Authors:  S J Perkins; L P Chung; K B Reid
Journal:  Biochem J       Date:  1986-02-01       Impact factor: 3.857

Review 5.  Alpha 1-acid glycoprotein (orosomucoid): pathophysiological changes in glycosylation in relation to its function.

Authors:  W van Dijk; E C Havenaar; E C Brinkman-van der Linden
Journal:  Glycoconj J       Date:  1995-06       Impact factor: 2.916

Review 6.  Structure, biosynthesis and functions of glycoprotein glycans.

Authors:  E G Berger; E Buddecke; J P Kamerling; A Kobata; J C Paulson; J F Vliegenthart
Journal:  Experientia       Date:  1982-10-15

7.  Site-Specific Mapping of Sialic Acid Linkage Isomers by Ion Mobility Spectrometry.

Authors:  Miklos Guttman; Kelly K Lee
Journal:  Anal Chem       Date:  2016-05-02       Impact factor: 6.986

8.  Oligosaccharides as receptors for JC virus.

Authors:  Rika Komagome; Hirofumi Sawa; Takashi Suzuki; Yasuo Suzuki; Shinya Tanaka; Walter J Atwood; Kazuo Nagashima
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

9.  Building a PGC-LC-MS N-glycan retention library and elution mapping resource.

Authors:  Jodie L Abrahams; Matthew P Campbell; Nicolle H Packer
Journal:  Glycoconj J       Date:  2017-09-13       Impact factor: 2.916

10.  Sialyl Lewis(x) epitopes do not occur on acute phase proteins in mice: relationship to the absence of alpha3-fucosyltransferase in the liver.

Authors:  E C Havenaar; R C Hoff; D H van den Eijnden; W van Dijk
Journal:  Glycoconj J       Date:  1998-04       Impact factor: 2.916

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.